CHARLOTTE, NC
Psoriatic Arthritis Clinical Trials
9 studies are open to new patients near Charlotte NC, across five different drug routes. Notably, there are open doors whether you have never had a biologic or have already failed one. Compensation is provided for eligible participants.
9
Open Near Charlotte
5
Different Drug Routes
+/- $100
Per Visit
New here? Read how this page works
First, one thing decides which of these is open to you, and it is not how bad your joints are. So here is the order to work through.
- Write down every drug you have already taken. Because that list, not your symptoms, decides which studies are open to you.
- Get your tender and swollen joint counts. Notably, nearly every adult study needs at least 3 of each, measured twice.
- Ask for your CRP number. In fact, two studies will not take you without a certain level, and a normal CRP fails you even with visibly swollen joints.
- Finally, tap the button. Then we check you against all of them at once and tell you when a new one opens.
Of course, checking never signs you up for anything. You are only seeing where you might fit.
The 9 Studies Open Near Charlotte
Seven are for adults and two are for children. However, one more reads as recruiting and takes only people from its parent study.
The seven adult drug studies
What routes you here is not how bad your joints are. Instead, it is what you have already taken.
A Pill, If You Have Never Been on a Biologic
Takeda / Drug
A once daily tablet that blocks the relay inside the immune cell, tested against a dummy and against an active drug. This is the version of the study built for people starting from scratch.
Payment is not published.
Check eligibility →More details
Why researchers are excited: most joint studies want people who have already failed something. So a study that requires the opposite is a rare open door if you are early in treatment.
Who this study is looking for
- Age 18 or over, meeting the standard CASPAR criteria
- Also, symptoms for at least 3 months
- Besides that, at least 3 tender and 3 swollen joints, at screening and again on day one
- Finally, you have never taken a biologic for anything
Probably not a fit if: you have taken any biologic, ever, even briefly. Also, any past TYK2 pill rules you out, which now includes the one approved for this condition in March 2026. So if your doctor is about to start you on that, have this conversation first.
- Placebo group: Real tablet against a dummy and against an active drug. The ratio and the dummy period are not published.
- How long: About 60 weeks.
- Clinic visits: Not published on the public record.
- Phone calls: Not published on the public record.
- Most invasive part: A tablet, so no study injections at all. Also, blood draws, skin scoring, and a full joint exam where 68 joints are pressed and 66 checked for swelling.
- Setting: Outpatient.
- Where it runs: Accellacare of Hickory, Hickory NC 28602.
- Drive from Charlotte: Hickory is about 60 miles northwest, so roughly an hour and 5 minutes.
- Worth knowing: this site is in Hickory, and two other studies list a Hickory address whose own status reads completed. This is the one that is genuinely open there.
- Full study record: View on ClinicalTrials.gov →
The Same Pill, Whatever You Have Already Tried
Takeda / Drug
The same once daily tablet, in the version that takes both people who have never had a biologic and people who have. The two groups are simply counted separately.
Payment is not published.
Check eligibility →More details
Why researchers are excited: on prior treatment grounds this is the most open door of the seven adult studies here. So it is the first call for most people who have already been through something.
Who this study is looking for
- Age 18 or over, meeting the standard CASPAR criteria
- Also, symptoms for at least 3 months before screening
- Besides that, at least 3 tender and 3 swollen joints, twice
- Finally, at least one psoriasis patch 2 cm across, or psoriasis nail changes
Probably not a fit if: you have taken a TYK2 pill before. That includes the one approved for this condition on 6 March 2026, and as more people start it, this door narrows month by month. Also, non plaque psoriasis and untreated TB rule you out.
- Placebo group: Real tablet against a dummy, and the ratio is not published.
- How long: Up to 60 weeks.
- Clinic visits: Not published on the public record.
- Phone calls: Not published on the public record.
- Most invasive part: A tablet, so no study injections. Also, blood draws, skin and nail scoring, a full joint exam and questionnaires.
- Setting: Outpatient.
- Where it runs: DJL Clinical Research, Charlotte NC 28210.
- Drive from Charlotte: This one is inside Charlotte, so no satellite town drive is involved.
- Ask this before anything else: if you are on a biologic now, you almost certainly come off it before day one. That washout is not published, and it decides how long your joints go untreated.
- Full study record: View on ClinicalTrials.gov →
The Skin Pill, Now Tested on the Joints
Janssen / Drug
This is the once daily pill approved for plaque psoriasis on 18 March 2026, the first of its kind. The question here is whether the same pill also works on the joints.
Payment is not published.
Check eligibility →More details
Why researchers are excited: it is the most immediately useful study in this city. Notably, the drug is already approved for the skin, so a great deal is already known about it in people.
Who this study is looking for
- Still active despite a standard drug, apremilast, or one biologic
- Also, diagnosed at least 3 months ago, meeting CASPAR criteria
- Besides that, at least 3 tender and 3 swollen joints, plus a CRP of 0.1 or higher
- Finally, one psoriasis patch 2 cm across or more, or nail changes
Probably not a fit if: you have had two or more biologics. One is allowed and two is not, which catches people who have cycled through several drugs. Also, a normal CRP fails you here, and fibromyalgia bad enough to confuse the joint count is a bar.
- Placebo group: Real tablet against a dummy, and the ratio is not published.
- How long: The main read comes at week 16, and the study runs to 2028, so expect follow up well beyond a year.
- Clinic visits: Not published on the public record.
- Phone calls: Not published on the public record.
- Most invasive part: A tablet, so no study injections. Also, blood draws that must go to the study’s own lab rather than yours, joint exams and skin scoring.
- Setting: Outpatient.
- Where it runs: Joint and Muscle Research Institute, Charlotte NC 28204.
- Drive from Charlotte: This one is inside Charlotte, so no satellite town drive is involved.
- Check your CRP first: a real share of people with clearly active disease have a normal CRP. So if yours runs normal, you can fail screening here despite obviously swollen joints.
- Full study record: View on ClinicalTrials.gov →
For People a TNF Drug Did Not Help
MoonLake / Drug
A small antibody fragment that blocks two arms of IL-17, tested against a dummy and against an approved drug. This one is built only for people a TNF blocker did not work for.
Payment is not published.
Check eligibility →More details
Why researchers are excited: if you are randomised to the comparison arm you receive a real approved drug rather than a dummy. So the downside of joining is meaningfully smaller here than in a two arm study.
Who this study is looking for
- Age 18 or over, meeting CASPAR criteria, with symptoms for 6 months
- Also, at least 3 tender and 3 swollen joints
- Besides that, active plaque psoriasis now, or a skin doctor confirmed history of it
- Finally, A TNF blocker was tried and did not work well enough, or you could not tolerate it
Probably not a fit if: you have had any non TNF biologic. That is the commonest reason people are turned away here. Also, a positive rheumatoid factor or anti-CCP rules you out, and so does inflammatory bowel disease.
- Placebo group: Four groups. Two doses of the study drug, a dummy, and an approved drug. The ratio is not published.
- How long: The main read comes at week 16, and the study runs to January 2027.
- Clinic visits: Not published on the public record.
- Phone calls: Not published on the public record.
- Most invasive part: Injections under the skin, for the study drug and for the comparison drug. Also, blood draws including rheumatoid factor and anti-CCP at screening, joint exams and skin scoring.
- Setting: Outpatient.
- Where it runs: Clinical site, Charlotte NC 28262.
- Drive from Charlotte: This one is inside Charlotte, so no satellite town drive is involved.
- Ask about the washout: you have been on a TNF blocker by definition, and you cannot take it alongside the study drug. Notably, those drugs clear at very different speeds, so the gap varies a lot.
- Full study record: View on ClinicalTrials.gov →
An Earlier Stage Study, With Several Doses
Janssen / Drug
A mid stage study testing several doses side by side against a dummy, to work out which dose is right. It carries more uncertainty than the late stage studies here.
Payment is not published.
Check eligibility →More details
Why researchers are excited: with several dose groups your chance of landing on the dummy is usually lower than in a two arm study. However, the exact odds here are not published, so ask.
Who this study is looking for
- Diagnosed at least 3 months ago, meeting CASPAR criteria
- Also, at least 3 tender and 3 swollen joints, plus a CRP of 0.1 or higher
- Besides that, one of the recognised joint patterns for this condition
- Finally, active plaque psoriasis, with a patch 2 cm or bigger, or nail changes
Probably not a fit if: fibromyalgia or arthritis wear can rule you out, if the doctor judges it would muddle the joint count. That catches more people than expected, because these often travel together. Also, non plaque psoriasis and a cancer in the past 5 years are bars.
- Placebo group: Several dose groups against a dummy. The number of groups and the ratio are not published.
- How long: The main read is at week 16, with safety to week 20 and the study running to 2027.
- Clinic visits: Not published on the public record.
- Phone calls: Not published on the public record.
- Most invasive part: Whether the drug is a tablet or an injection is not published, so ask, because it changes the burden a lot. Also, blood draws, joint exams, skin scoring and questionnaires.
- Setting: Outpatient.
- Where it runs: Joint and Muscle Research Institute, Charlotte NC 28204.
- Drive from Charlotte: This one is inside Charlotte, so no satellite town drive is involved.
- Worth asking: the rules here do not state a limit on how many biologics you have had, unlike its late stage sister study. So if you have cycled through several drugs, this is worth a call.
- Full study record: View on ClinicalTrials.gov →
Where the Dummy Period Is Published and Short
Merck / Drug
A mid stage study of an antibody against a new target, with the dummy period capped at 16 weeks. After that, everyone who carries on moves to the real drug.
Payment is not published.
Check eligibility →More details
Why researchers are excited: most studies here do not publish how long you could be on a dummy. This one does, and it is 16 weeks. So you know the worst case before you agree to anything.
Who this study is looking for
- Age 18 to 80, which is the only adult study here with an upper limit
- Also, diagnosed at least 6 months ago, meeting CASPAR criteria
- Besides that, active plaque psoriasis now, or a documented history of it
- Finally, either you have never had a biologic, or one did not work well enough
Probably not a fit if: any arthritis that started before you were 17. That rules out adults who had juvenile arthritis, and few people expect it. Also, any other inflammatory joint disease, and any active infection, are bars.
- Placebo group: Real drug against a dummy for 16 weeks, then everyone who continues gets the real drug. The ratio is not published.
- How long: Up to about 142 weeks if you take the full optional extension. So this is the longest adult commitment here.
- Clinic visits: Not published on the public record.
- Phone calls: Not published on the public record.
- Most invasive part: An antibody, so an injection or a drip, and the record does not say which. Ask, because it matters. Also, blood draws, joint exams, skin scoring and questionnaires.
- Setting: Outpatient.
- Where it runs: Joint and Muscle Research Institute, Charlotte NC 28204.
- Drive from Charlotte: This one is inside Charlotte, so no satellite town drive is involved.
- Two things to weigh: the dummy period is capped and published, which is unusually fair. However, the full commitment runs to nearly three years, which is the longest on this page.
- Full study record: View on ClinicalTrials.gov →
The One Where You Keep What Is Working
Eli Lilly / Drug
You keep taking the biologic you already started, and a weekly weight loss shot is added on top. There is no dummy anywhere in this study.
Payment is not published.
Check eligibility →More details
Why researchers are excited: every other adult study here asks you to come off your treatment and risk a flare. This one requires you to stay on it, and that makes it the realistic option if you are stable.
Who this study is looking for
- Active psoriatic arthritis diagnosed by a joint specialist
- Also, A BMI of 30 or above, or 27 to 30 with a weight linked condition
- Besides that, you have been on ixekizumab for about 3 months, give or take one
- Finally, you can start the added shot within 30 days of that decision
Probably not a fit if: you have ever taken a GLP-1 drug. Any past Ozempic, Wegovy or Mounjaro shuts this door. Also, the drug window is narrow, so more than 4 months or less than 2 means no.
- Placebo group: None at all. Open label and single arm, so everyone gets the real drug and knows it.
- How long: Up to 12 months.
- Clinic visits: Not published in full. Readings are taken at the start, month 6 and month 12.
- Phone calls: Not published on the public record.
- Most invasive part: A weekly shot you give yourself, on top of the joint shot you already take. Also, joint counts, skin measures, weight and many forms. No drips and no biopsy.
- Setting: Outpatient.
- Where it runs: Onsite Clinical Solutions, Salisbury NC 28144.
- Drive from Charlotte: Salisbury is about 45 miles northeast, so roughly 50 minutes on I-85.
- Why this one is different: it is one of only two studies here that requires you to keep a biologic rather than stop one. So if you are stable, start here.
- Full study record: View on ClinicalTrials.gov →
The two for children and young people
One gives every child the real drug and no dummy. The other gives no drug at all and changes nothing.
For Children, and Nobody Gets a Dummy
Novartis / Drug
An approved adult drug, given by drip, measured carefully in children to work out the right dose by age and weight. Every child in it receives the real drug.
Payment is not published.
Read the details →More details
Why researchers are excited: drugs get approved in adults and then children are dosed by judgement for years. So a study built to fix that gap matters more than its small size suggests.
Who this study is looking for
- Aged 2 to under 18, and at least 10 kilograms
- Also, juvenile psoriatic arthritis confirmed at least 6 months ago
- Besides that, at least 3 active joints now
- Finally, an anti-inflammatory and a standard drug were both tried and did not work
Probably not a fit if: your child takes a standard drug other than methotrexate. Leflunomide or sulfasalazine must be changed first. Also, active bowel disease or active eye inflammation rules them out, and eye inflammation is common here.
- Placebo group: None. Open label and single arm, so every child receives the real drug and everyone knows it.
- How long: Up to 6 years, with an optional extension. So this is a very long commitment.
- Clinic visits: Published in detail, and it is front loaded. Weekly visits sit between roughly week 9 and week 12, then it spaces out.
- Phone calls: Not published on the public record.
- Most invasive part: Drips, and frequent blood draws. Blood is taken before and at the end of each drip, because measuring the drug level is the whole point. For a small child that is the main burden and deserves a frank conversation.
- Setting: Outpatient.
- Where it runs: Levine Children’s Hospital, Charlotte NC 28203.
- Drive from Charlotte: This one is inside Charlotte, so no satellite town drive is involved.
- The reassurance for a parent: there is no dummy anywhere in this study. However, methotrexate can continue, and a steady low dose steroid and one anti-inflammatory can too.
- Full study record: View on ClinicalTrials.gov →
The Register for Children and Young People
Duke University, with the childhood rheumatology alliance / Registry
A long running national register of children and young people with rheumatic disease. No drug is given and nothing about their treatment changes.
Payment is not published.
Read the details →More details
Why researchers are excited: it exists to catch rare and delayed safety problems with the drugs used in children, which no single drug study is ever large enough to find.
Who this study is looking for
- The disease began before age 19
- Also, they are 21 or younger when they join
- Besides that, A parent or guardian can give written consent
- Finally, they are willing to be contacted by study staff later
Probably not a fit if: they are over 21 when joining. That is the only published exclusion, and taking part is open regardless of what treatment they have had or are having now.
- Placebo group: Neither. It is a register, so there is no randomisation, no dummy and no study drug.
- How long: Each young person is followed with a goal of 10 years.
- Clinic visits: Not published. Information is gathered around ordinary clinic appointments rather than extra visits.
- Phone calls: Not published on the public record.
- Most invasive part: Minimal. Clinical details, treatments and questionnaires are recorded. No study drug, no drips, no injections and no scans.
- Setting: Outpatient.
- Where it runs: Levine Children’s Hospital, Charlotte NC 28203.
- Drive from Charlotte: This one is inside Charlotte, so no satellite town drive is involved.
- Worth knowing: it takes part regardless of what treatment your child has had, because the register needs untreated comparisons as well as treated ones.
- Full study record: View on ClinicalTrials.gov →
Not sure which one fits you?
First, answer a few quick health questions. Then we check you against every study we track. Also, no account and no paperwork.
See if I may fit one of these studies →What Is Actually Changing in Psoriatic Arthritis
The joints do not grow back. That is why this is treated faster than the skin.
What It Is, and Who Gets It
It is joint swelling that turns up in people who have psoriasis, or who have it in the family. Roughly one in three people with psoriasis will get it. The immune system attacks joints, the points where tendons anchor into bone, and sometimes the spine. So the skin usually comes first, often by years, though it can arrive in either order.
Why It Is Treated With More Urgency
Skin clears and comes back. Joints do not. Left alone, this wears joints away for good, and that damage cannot be undone by any drug. So the whole approach is built around getting on top of it early rather than waiting to see. Notably, that is the single biggest difference from treating the skin alone.
Five Patterns, Not One Disease
It can hit the small joints of hands and feet, or the joints nearest the fingernails, or the point where a tendon meets bone, most often the Achilles or the sole of the foot. It can swell a whole finger or toe into a sausage shape, which is nearly unique to this family of disease. Also, it can inflame the spine, giving back pain that is worse with rest and better with movement.
The Two Numbers That Decide Everything
Ask for your tender joint count out of 68 and your swollen joint count out of 66. Nearly every adult study here needs at least 3 of each, measured at screening and again on day one. So people are routinely turned away because on the day they happened to have 2 swollen joints rather than 3. In fact, the disease moves, and so does whether you qualify.
Ask for Your CRP Too
It is a blood marker of swelling, and two studies here will not take you without a certain level of it. However, a real share of people with clearly active disease have a normal CRP. So if yours runs normal you can fail screening while your joints are visibly swollen, which is as unfair as it sounds. Generally, knowing the number before you book screening saves a wasted trip.
The Question That Routes You
It is not how bad your joints are. It is what you have already taken. One study here requires that you have never had a biologic. Another requires that a TNF blocker failed you. One allows exactly one previous biologic and bars two. So the list of what you have tried is the single most useful thing to bring to a first phone call.
March 2026 Gave This an Oral Option
On 6 March 2026 the first TYK2 pill was approved for this condition, the first genuinely new kind of pill for it in years. Before that, an oral option meant methotrexate, apremilast, or a JAK pill carrying heavy warnings. Meanwhile, for people who have refused injections for years, that changed the conversation completely.
And It Created a Door That Is Closing
Here is the part nobody tells you. Two studies here bar anyone who has taken a TYK2 pill before. So as more people are started on the newly approved one, those two studies will disqualify more and more people. If your doctor is about to start you on it and you are also weighing a study, that is a conversation to have first. Also, it is not an argument against the drug, only a reason to sequence the decision properly.
Research Sites Near Charlotte
Two research practices in the city carry most of these, with others in Hickory and Salisbury. But sites add new studies all the time, so it is worth knowing what sits near you.
Atrium Health
Multiple Charlotte locations / 161+ active studies
Crohn’s, Heart Failure, COPD, Dementia, Type 2 Diabetes, Hypertension
Charlotte’s biggest health system. It is tied to Wake Forest University School of Medicine. Also, it runs far more trials than anyone else nearby.
Visit Website →
American Health Research Network
Ballantyne, NC 28277 / 25 to 30+ active studies
Asthma, COPD, Chronic Cough, Type 2 Diabetes
Led by Dr. Selwyn Spangenthal. It is the biggest private lung research group in Charlotte. Specifically, it has 4 offices: Charlotte, Rock Hill, Lake Norman, and Charleston.
Visit Website →
Monroe Biomedical Research
Monroe, NC / 17+ active studies
Asthma, COPD, Hypertension, Obesity, Ulcerative Colitis
Notably, one of the 5 busiest research sites in the country. Its 6,300 sq ft space can host overnight stays. It is also an SCRS Global Impact Partner.
Visit Website →
Clinical Research of Gastonia
Gastonia, NC / 11+ active studies
Asthma, COPD, Chronic Cough, Idiopathic Hypersomnia
Led by Dr. Anup Banerjee. Its 3,500 sq ft space sits next to CaroMont Regional Medical Center. Also, it has been running for over 10 years.
Visit Website →
OnSite Clinical Solutions
Ballantyne, NC 28277 / 10+ active studies
Ulcerative Colitis, Crohn’s, COPD, Heart Failure, Atopic Dermatitis
It works with Charlotte doctors in heart, gut, skin, nerve, and joint care. Besides, it runs studies from Phase I through Phase IV.
Visit Website →
Flourish Research
Matthews, NC 28105 / 4+ active studies
Alzheimer’s Disease, Early Alzheimer’s, Alzheimer’s-Related Psychosis
Led by Dr. M. Reza Bolouri. He has 20+ years in Alzheimer’s research. The site is an Alzheimer’s Center of Excellence. In fact, its network has finished 5,500+ trials.
Visit Website →
New Hope Clinical Research
SouthPark, NC 28211 / 4+ active studies
Major Depression, Schizophrenia, Bipolar Disorder
Led by Dr. Kurian Abraham. It runs Phase I through IV studies and has 30 beds for overnight stays. Its last FDA audit came back clean. Also, it has finished 200+ brain studies.
Visit Website →
Queen City Clinical Research
SouthPark, NC 28211 / 2+ active studies
Chronic Pain, Chronic Migraine, Osteoarthritis
Led by Dr. Leonardo Kapural, a former Cleveland Clinic professor. Notably, he has written 200+ journal articles. On top of that, many call this the biggest pain research site in the country.
Visit Website →
Novant Health
Multiple Charlotte locations / Several active studies
Cardiovascular Disease, Obesity, Hypertension
One of the biggest health systems in the Carolinas. Its Heart and Vascular Institute runs heart studies and sees a lot of patients.
Visit Website →
DLVSC
4 Charlotte-area offices / 1+ active studies
Eczema, Psoriasis, Rosacea
Led by Dr. Gilly Munavalli. This award-winning skin practice owns 50+ FDA-approved lasers and devices. Also, it has its own research team.
Visit Website →
DelRicht Research
South Charlotte, NC 28210 / 1+ active studies
Bipolar Disorder, Bipolar Depression
Part of a national network of mental health research sites. Currently, it runs the azetukalner bipolar depression trial in Charlotte. Previously, it ran other mental health studies.
Visit Website →
TMS of the Carolinas
South Charlotte, NC 28210 / 1+ active studies
Major Depression, Treatment-Resistant Depression
A specialty site for brain stimulation care. It runs the fast TMS study that packs 6 weeks into 2.
Visit Website →What to Expect in a Psoriatic Arthritis Study
New to studies? Here is how one works, step by step.
01
Prescreening
First comes a short phone call or online form. Also, it takes about 10 to 15 minutes. The staff check whether you might fit. Then they tell you what is open.
02
Screening Visit
Next the clinic runs the tests that decide it, which usually means blood work. Also, they go through the consent form line by line, and you can bring somebody with you.
03
Treatment Period
Then the study begins. So you take the study drug or the placebo on the agreed schedule. Meanwhile, your own doctor keeps managing everything else.
04
Follow-Up
Finally, there is a check in period at the end. Also, your own doctor gets the results, and you can stop at any point without affecting your care.
Psoriatic Arthritis Trial FAQs
Real answers about psoriatic arthritis studies near Charlotte NC.
Is there a study for this near Charlotte?
Yes, nine are open, which makes this one of the better places in the Southeast for it. Seven are adult drug studies across five different routes, and two are for children and young people. Notably, there are open doors whether you have never had a biologic or have already failed one or more. However, one more reads as recruiting and takes only people who completed its parent study, so we do not count it.
What decides which studies I can join?
What you have already taken, and it is not close. One study requires that you have never had a biologic. Another requires that a TNF blocker failed you. One allows exactly one previous biologic and bars two or more. So bring the full list of what you have tried to the first phone call, because it routes you faster than anything else.
Why do I need 3 swollen joints?
Because that is the entry bar for nearly every adult study here, measured at screening and again on day one. It is counted out of 66 for swelling and 68 for tenderness, and a doctor presses each one. However, the disease moves, so people are turned away for having 2 swollen joints on the day rather than 3. Generally, booking screening during a good spell is the wrong move.
What is CRP and why does it matter?
It is a blood marker of swelling, and two studies here will not take you without a certain level. However, a real share of people with clearly active disease have a normal CRP. So you can fail screening while your joints are visibly swollen, which is as unfair as it sounds. Also, knowing your number before you book saves a wasted trip.
Is there a pill for this now?
Yes, and it is very recent. The first TYK2 pill was approved for this condition on 6 March 2026. Before that, an oral option meant methotrexate, apremilast, or a JAK pill carrying heavy warnings. So for people who have refused injections for years, that changed the conversation. Meanwhile, a second oral drug approved for the skin in March 2026 is being tested here for the joints.
Is there a door that is closing?
Yes, and it is worth knowing before your next appointment. Two studies here bar anyone who has taken a TYK2 pill before, and one was approved for this condition in March 2026. So as more people are started on it, those two studies will turn away more and more people. However, that is not an argument against the drug, only a reason to sequence the decision properly.
Will I have to stop my treatment?
For most of these, yes, and the washout is the question to lead with. You generally cannot take a biologic alongside a study drug, so you come off it before day one. The exact gaps are not published, and they matter, because they decide how long your joints go untreated. However, one study here requires you to keep your biologic rather than stop it.
Why is this treated faster than my skin?
Because skin clears and comes back, and joints do not. Left alone, this wears joints away permanently, and no drug puts that back. So the whole approach is built around getting on top of it early rather than waiting to see. Notably, that is the single biggest difference from treating psoriasis on its own.
Does it cost anything to be on the list?
No. There is no cost, and no insurance is needed. Tether is a nonprofit list, so we do not run studies and we are not paid to send you anywhere. Also, being on the list never enrolls anyone in anything. You would always call the clinic yourself.
Where can I get joint care near Charlotte NC?
Atrium Health and Novant Health both run joint services, and two research practices sit inside the city. Also, ask for a joint specialist rather than skin care alone, because the joint damage is the part that does not recover. Generally, your own doctor can refer you. Meanwhile, if you have a swollen finger or heel pain and psoriasis, say all three things in the same sentence.
Ready to Explore a Study?
Check your eligibility, or just reach out to our Charlotte team. No pressure. Also, no sales pitch.
← Back to All Clinical TrialsSources
- LATITUDE-PsA-3001 zasocitinib study in biologic naive patients, ClinicalTrials.gov NCT06671483
- LATITUDE-PsA-3002 zasocitinib study, ClinicalTrials.gov NCT06671496
- ICONIC-PsA 2 icotrokinra study, ClinicalTrials.gov NCT06807424
- IZAR-2 sonelokimab study in TNF inadequate responders, ClinicalTrials.gov NCT06641089
- VELOTA JNJ-88545223 dose ranging study, ClinicalTrials.gov NCT07321873
- Tulisokibart MK-7240-015 study, ClinicalTrials.gov NCT07486960
- TOGETHER AMPLIFY-PsA, tirzepatide added to ixekizumab, ClinicalTrials.gov NCT06864026
- Intravenous secukinumab dosing study in juvenile psoriatic arthritis, ClinicalTrials.gov NCT06751238
- CARRA paediatric rheumatic disease registry, ClinicalTrials.gov NCT02418442
- Sonelokimab open label extension, listed separately because it takes only people from the parent study, ClinicalTrials.gov NCT07223138
- Bristol Myers Squibb: FDA approval of deucravacitinib for active psoriatic arthritis, 6 March 2026
Study details and per-site recruiting status verified against ClinicalTrials.gov on August 16, 2026. One further study in Charlotte reads as recruiting but accepts only people who completed its parent study, so it is not counted here. Two studies listing a Hickory NC address were excluded because that site’s own status is listed as completed. Study availability and criteria change; the research clinic confirms everything before you enroll.